Drug intelligence / Profile preview

FRE03

Development stage: Preclinical
Lead developer: Freya Biosciences
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Topical, Intravaginal

Overview

FRE03 appears to be an early internal Freya Biosciences development code associated with the company's bacterial vaginosis focused vaginal microbiome program, but public sources do not clearly define the exact corresponding product identity, composition, or whether it maps directly to a later disclosed candidate such as FB101, FB301, or FB401. Freya Biosciences develops vaginal microbial immunotherapies intended to restore a Lactobacillus-dominant vaginal microbiome and modulate local inflammation or immune dysregulation in women's health indications including bacterial vaginosis, infertility-related implantation failure, and preterm birth risk. Because the exact molecular or consortium-level identity of FRE03 is not publicly resolved from the available evidence, its precise mechanism of action, modality-specific composition, and development stage cannot be assigned with confidence.

Beyond the preview

Go deeper on FRE03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FRE03.

Explore the full profile